# Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06380660/  
OnCo record `nct06380660` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ACE-86225106 tablet in ovarian cancer and prostate cancer, run by Acerand Therapeutics (Shanghai) Limited, active and no longer recruiting.

## Summary

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06380660 by Acerand Therapeutics (Shanghai) Limited, with 298 participants enrolled, started 2024-03-22 and due to reach its primary completion in 2028-12-21. Interventions recorded: ACE-86225106 tablet.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06380660
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors
- Sponsor: Acerand Therapeutics (Shanghai) Limited
- Enrolled: 298

## Sources

- ClinicalTrials.gov NCT06380660: https://clinicaltrials.gov/study/NCT06380660

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct06380660.json